ReviewSurvey of ophthalmology
Neurodevelopmental outcomes in preterm infants with retinopathy of prematurity.
Review in Survey of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Mapping evidence on maternal metabolic conditions and child neurodevelopment in the Caribbean: a scoping review.Frontiers in nutrition · 2026Pooled it
- Pooled it
- Fixation and saccadic performance throughout childhood in children born preterm: A multicenter eye-tracking study.Pediatric research · 2026Article
- Retinopathy of Prematurity and Neurodevelopmental and Quality-of-Life Outcomes at 10 Years of Age.American journal of perinatology · 2026Article
- Systematic review and meta-analysis of risk prediction models for retinopathy of prematurity in preterm infants.Biomedical reports · 2025Article
- From Screening to Therapy: A Personalized Approach to ROP in a National NICU Setting.Journal of personalized medicine · 2025Article
- Long-term follow-up of the cognitive function in children after intravitreal ranibizumab for retinopathy of prematurity.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Article
- Intra-Anterior Chamber Injection of Ranibizumab in Advanced Pediatric Vitreoretinal Diseases.JAMA ophthalmology · 2024Observational
- Interdisciplinary collaborative eye examinations to protect preterm infant neurodevelopment: a quality improvement project.Frontiers in psychology · 2024Article
- Association between severe retinopathy of prematurity (ROP) and poor motor neurodevelopmental outcome.Indian journal of ophthalmology · 2023Review
- Exposure of preterm neonates receiving total parenteral nutrition to phthalates and its impact on neurodevelopment at the age of 2 months.Scientific reports · 2023Article
- Retinopathy of prematurity and neurodevelopmental outcomes in preterm infants: A systematic review and meta-analysis.Frontiers in pediatrics · 2023Review
- Pulmonary Hypertension in Preterm Infants Treated With Laser vs Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity.JAMA ophthalmology · 2022Article
- Neurovascular abnormalities in retinopathy of prematurity and emerging therapies.Journal of molecular medicine (Berlin, Germany) · 2022Review
- Association of Docosahexaenoic Acid and Arachidonic Acid Serum Levels With Retinopathy of Prematurity in Preterm Infants.JAMA network open · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Over the past decade there has been a paradigm shift in the treatment of retinopathy of prematurity (ROP) with the introduction of antivascular endothelial growth factor (anti-VEGF) treatments. Anti-VEGF agents have the advantages of being easier to administer, requiring less anesthesia, having the potential for improved peripheral vision, and producing less refractive error than laser treatment. On the other hand, it is known that intravitreal administration of anti-VEGF agents lowers VEGF levels in the blood and raises the theoretical concern of intraocular anti-VEGF causing deleterious effects in other organ systems, including the brain. As a result, there has been increased attention recently on neurodevelopmental outcomes in infants treated with anti-VEGF agents. These studies should be put into context with what is known about systemic comorbidities, socioeconomic influences, and the effects of extreme prematurity itself on neurodevelopmental outcomes. We summarize what is known about neurodevelopmental outcomes in extremely preterm infants with ROP, discuss the implications for determining the neurodevelopmental status using neurodevelopmental testing as well as other indicators, and review the existing literature relating to neurodevelopmental outcomes in babies treated for ROP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.